reference standard comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
To induce childbirth (parturition) or abortion (PGE2 or PGF2(misoprostol), with or without mifepristone, a progesterone antagonist) Induction of labour To prevent closure of ductus arteriosus in newborns with particular cyanotic heart defects (PGE1) As a vasodilator in severe Raynaud syndrome or ischemia of a limb In pulmonary hypertension In treatment of glaucoma (as in bimatoprost ophthalmic solution, a synthetic prostamide analog with ocular hypotensive activity) (PGF2α) To treat erectile dysfunction or in penile rehabilitation following surgery (PGE1 as alprostadil). To measure erect penis size in a clinical environment To treat egg binding in small birds
=== Government efficiency === In 1997, Rolling Stone published a comprehensive snapshot of the US government's implementation of the war on drugs, spanning 44 federal agencies and hundreds of thousands of government workers, and without unified management, oversight, or cohesive strategy. Among the agencies there were over a dozen separate drug intelligence operations. The White House's Office of National Drug Control Policy, home of the drug czar and ostensibly the coordinating agency, had a staff of 150, and a $36 million budget; the overall federal drug war budget for 1998 was $16 billion. Most of the agencies involved did not report to the ONDCP, instead to one of 13 congressional appropriations subcommittees. The largest single share of the budget, $2 billion, went to the Bureau of Prisons. Federal agencies also passed on billions of anti-drug dollars to the states, with little oversight or accountability. In 2024, the ONDCP requested $461 million of a $46 billion federal budget allocated across some 50 federal agencies.
liraglutide (Victoza for type 2 diabetes, Saxenda for weight management, manufactured by Novo Nordisk), approved in 2010/2014 dulaglutide (Trulicity, manufactured by Eli Lilly), approved in 2014 semaglutide (Ozempic and Rybelsus for diabetes, Wegovy for weight management, manufactured by Novo Nordisk), approved in 2021/2019/2021 tirzepatide (a GIP analog with dual GLP-1 receptor and GIP receptor agonism; Mounjaro for diabetes, Zepbound for weight management, manufactured by Eli Lilly), approved in 2022/2024 Discontinued:
Sources: en.wikipedia.org
Social learning theory, as originally proposed by Albert Bandura, holds that behavior is shaped by the reciprocal relationships between personal factors, the external environment, and the behavior itself (a principle known as reciprocal determinism). Applied to addiction, this frames drug use as arising from the interaction between an individual's personal characteristics, their social environment, and drug-related behavior itself, and characterizes addiction as a chronically evolving biopsychosocial disorder. On this account, effective treatment should target every node of the model and the relationships between them, rather than any single factor in isolation.
== Drug interactions == Thiotepa can have various interactions with other medications or therapies that can impact patient safety and treatment efficacy. Aprepitant, a drug that prevents nausea and vomiting that may occur during chemotherapy, inhibits CYP-enzymes, which decrease the metabolism of thiotepa to tepa. Its importance is relatively minor because inhibition itself is small and due to the variability of thiotepa clearance in different individuals. The anti-seizure medication phenytoin induces the CYP3A4 enzyme. This leads to an increased rate of tepa formation from thiotepa, which highly influences its clearance and concentration. Higher local concentrations of the more reactive tepa can potentially induce hepatotoxicity. Additionally, cytotoxic drugs such as thiotepa can reduce the absorption of phenytoin leading to the increased risk of seizures. It is advised to avoid the use of both drugs simultaneously or decrease thiotepa doses. Myelosuppressive/myelotoxic agents such as melphalan, busulfan, treosulfan, and cyclophosphamide, as well as the concurrent use of thiotepa, may increase the risk of hematologic adverse reactions and pulmonary toxicity, as they share similar toxicity profiles. Additionally, the use of live attenuated vaccines (including yellow fever) poses a risk of systemic and potentially fatal infection, with the risk further heightened in patients who are already immunosuppressed due to their underlying disease.
Paul John Flory (June 19, 1910 – September 9, 1985) was an American chemist and Nobel laureate who was known for his work in the field of polymers, or macromolecules. He was a pioneer in understanding the behavior of polymers in solution, and won the Nobel Prize in Chemistry in 1974 "for his fundamental achievements, both theoretical and experimental, in the physical chemistry of macromolecules".
Xylazine is the most widely anesthetic agent used for short-duration operations in non-human animals. It does not have a medical use in humans. Pharmacokinetics of xylazine may be influenced by anesthesia since after an intravenous therapy about 1.1 mg/kg, the half-life of xylazine will increase to 118 minutes and the clearance will decrease to 6 mL/kg/min. Based on a recent study, if injecting the morphine, which is 0.1 or 0.2 mg/kg, in the vein at the same time can extend the terminal half-life to about 150 minutes and the clearance will not be influenced.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.